Hepatitis B and D Protocols

1. Front Matter

   Pages i-xxiv

   PDF

2. Detection of Viral Markers

   1. Front Matter

      Pages 1-1

      PDF

   2. Overview of Commercial HBV Assay Systems

      • Stefan Zeuzemro

      Pages 3-13

   3. Detection of HBV DNA in Serum Using a PCR-Based Assay

      • Hau Tim Chung

      Pages 15-20

   4. Detection of HBV DNA by Oligonucleotide Probing

      • Hsiang Ju Lin

      Pages 21-28

   5. Detection of HBV RNA in Serum of Patients

      • Wei Zhang, Hans Jörg Hacker, Maria Mildenberger, Qin Su, Claus H. Schröder

      Pages 29-40

   6. Quantification of HBV Covalently Closed Circular DNA from Liver Tissue by Real-Time PCR

      • Scott Bowden, Kathy Jackson, Margaret Littlejohn, Stephen Locarnini

      Pages 41-50

   7. In Situ Hybridization for the Detection and Localization of HBV DNA in Liver Sections

      • Vicky C. H. Lai, Johnson Y. N. Lau

      Pages 51-55

   8. Quantitative Assay of Hepatitis B Surface Antigen in Serum or Plasma Using Laurell Electrophoresis

      • Wolfram H. Gerlich, Ulrike Wend, Dieter Glebe

      Pages 57-63

   9. In Situ Detection of Hepatitis B Viral Antigens

      • Jane W. S. Fang, Johnson Y. N. Lau

      Pages 65-69

   10. Detection of Hepatitis B Virus X Antigen by Immunohistochemistry and Western Blotting

       • Jie Liu, Mark A. Feitelson

       Pages 71-84

   11. Detection of Serum HDV RNA by RT-PCR

       • Antonina Smedile, Maria Grazia Niro, Mario Rizzetto

       Pages 85-93

   12. Nonradioisotopic In Situ Hybridization for HDV RNA

       • Francesco Negro

       Pages 95-98

   13. Detection and Characterization of Small and Large HDV Antigens

       • Thomas B. Macnaughton, Michael M. C. Lai

       Pages 99-105

   14. Immunohistochemical Detection of Hepatitis Delta Antigen

       • Karim Abid, Francesco Negro

       Pages 107-111

3. Viral Genotypes and Variants

   1. Front Matter

      Pages 113-113

      PDF

   2. HBV Vaccine-Escape Variants

      • Ashraf A. Basuni, William F. Carman

      Pages 115-124

   3. HBV Genotyping and Analysis for Unique Mutations

      • Anna Ayres, Stephen Locarnini, Angeline Bartholomeusz

      Pages 125-149

   4. A One-Filter–Three-Probe Assay for Defective Interference (DI) Effects of Naturally Occurring Core Internal Deletion (CID) Variants of Human Hepatitis B Virus

      • Chiaho Shih, Ta-Tung Thomas Yuan

      Pages 151-163

   5. Detection of Hypermodified Middle-Envelope (M) Proteins Secreted from Naturally Occurring HBV Variants Containing a preS2 Internal Deletion

      • Chiaho Shih, Pei-Ching Tai

      Pages 165-173

Despite the availability of an effective vaccine, there are still 400 million people, worldwide who are chronically infected with hepatitis B virus (HBV). For them, the vaccine, as currently applied, has no value. Given the possible consequences of HBV infection, the number of those chronically infected with HBV presents an enormous public health challenge. For example, the major etiology of hepatocellular carcinoma (HCC) is chronic infection with HBV. Although fifth in cancer incidence, worldwide, HCC/liver cancer is the third leading cause of cancer death. The high mortality as- ciated with HCC arises because the disease is often detected late and is unresponsive to treatment. The number of deaths caused by PHCC is expected to rise over the next 20 years. Those chronically infected with HBV have a life risk of death to HCC of between 10 and 25%. Even the limited efficacy of drugs for the treatment of chronic HBV helps underscore the point that this disease is responsive to therapy. Drugs that target the polymerase (e. g. , hepsera and lamivudine) and interferon alpha represent two distinct strategies and show that both conventional antiviral and immunothe- peutic approaches can be used in management. However, the current inventory of therapeutics is inadequate. Interferon alpha is of limited value, only parenterally ava- able, and fraught with adverse reactions.

• Hepatitis
• antigen
• infection
• infections
• interferon
• vaccine
• virus
• infectious diseases

From the reviews:

"Both volumes provide an excellent reference for background information and detailed experimental investigations for both Hepatitis B and Hepatitis D. A major attribute of the volumes is that as they cover a wide range of subjects, the reader has the opportunity to access information they would not normally encounter. Volumes 1 and 2 are an excellent reference source and the methodologies described present the opportunity for both new and experienced researchers to study the molecular aspects of HBV and HDV infection."-SGM Quarterly

"...an excellent reference for background information and detailed experimental investigations for both Hepatitis B and Hepatitis D...." - Microbiology Today

"The book is an extremely comprehensive collection of valuable modern protocols on detection of HBV DNA in serum and liver … . In summary, the general layout of the book is of excellent quality. Details are painstakingly provided so that sophisticated readers can profit from first hand top quality information derived from people who have personally worked at the bench. The substantial number of references will also allow easy access to the specific literature in the field." (M. Mondelli, Digestive and Liver Disease, Vol. 37, 2005)

• Ribapharm Inc., Costa Mesa

  Robert K. Hamatake, Johnson Y. N. Lau

Policies and ethics